Search Menu

Scientific Research and R&D

Finnish Red Cross Blood Service performs active scientific research by which we want to increase biomedical knowledge on our areas of expertise. This can be achieved primarily by scientific publications and academic dissertations. The scientific research also creates the foundation for R&D projects in which we develop our products and services.


According to the present research strategy the focus areas for our research are

  • Biology of blood cells
    omics studies on aging of red cells, thrombocytes and extracellular vesicles produced by them
  • Understanding effects of blood donation on donor physiology and health
    collection of a large research cohort of 10 000 donors
    whole genome studies and biobanking as major tools
  • Immunogenetic compatibility of blood, stem cell and organ transplantation
    toward genome-wide compatibility 
  • Development of and research on advanced cell therapy products
    novel indications for our current ly-MSC product
    therapeutic potential of immune cells

We are co-authors in 30–40 scientific publications each year (see picture at the bottom of the page) and during the 60 year history of the Blood Service nearly 60 PhD theses have been done primarily in our laboratories. In addition to the topics of the current R&D focus, scientific publications have dealt with blood groups, stem cells and cord blood, haemostasis, the complement system and immunogenetics of autoimmune diseases.

Twelve senior level scientists of the Blood Service staff hold an adjunct professorship (“docentship”) and participate teaching and supervision of students at universities. We also organise courses (mainly in Finnish) for health care professionals on our areas of expertise, such as transfusion medicine, novel cell therapies and blood groups.

The major sources for external funding are TEKES, EVO, EU and Finnish Academy. During the past years, we have been able to obtain more than 600 000 euros per year from competitive sources for research and development.


​The FRCBS is a member of the ATMP and biomarker platforms
of the EATRIS infrastructure.